Monogram Biosciences Pharma Collaborations

Slides:



Advertisements
Similar presentations
Presentation for HL7 RCRIM and Clinical Genomics SIG HL7 Working Group Meeting San Diego, CA 21Jan2004.
Advertisements

1 HIV Drug Resistance Training Module 7: HIV Genotyping Assay Validation.
High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.
POSTER 82 CXCR4 using HIV-1 strains more abundant in PBMC than in plasma Chris Verhofstede 1 *, Linos Vandekerckhove 2, Veerle van Eygen 3, Kenny Dauwe.
Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.
Resistance Testing – Where Do I Start?
Office of Infectious Diseases Computational Challenges for Infectious Diseases Michael Shaw, PhD OID/Office of the Director.
“ The therapeutic effect of FIT- 06, GTU®-Multi-HIVB DNA vaccine, observed in HIV-1 infected people. Results of a Phase II trial”. Prof. Mart Ustav SVP,
Antiviral Immunity and Transmission June 19, 2011 Abst. #: TUAA0105 Maraviroc-resistant subtype B primary HIV-1 induced in vitro selection became highly.
Utilizing a Non-Commercial Real- Time PCR to Detect HIV-1 RNA in HIV Antibody Negative Diagnostic Sera Submitted to The Maryland Public Health Laboratory.
Affordable Resistance Testing for Africa (ART-A)
Improved Reflexive Testing Algorithm for Hepatitis C Infection Using Signal-to-Cutoff Ratios of a Hepatitis C Virus Antibody Assay K.K.Y. Lai, M. Jin,
ANIMAL MODELS HIV Cure Research Training Curriculum The HIV CURE training curriculum is a collaborative project aimed at making HIV cure research science.
1 HIV Curative Strategies: Key Research Priorities Deeks S, et al., (2013) Nat Rev Immunol. 12(8):
6/28/00TPED1 Resistance Testing: What is it? What does it mean? How does drug resistance emerge? Overview of methods Advantages and disadvantages Current.
Salvage Antiretroviral Therapy Guiding Principles, Strategies and the Role of Resistance Testing.
HIV and AIDS Human Immunodeficiency Virus (HIV) is the virus that causes Acquired Immunodeficiency Syndrome (AIDS).
Issues to Consider in HIV Resistance Testing Jason Tokumoto, MD National HIV/AIDS Clinicians’ Consultation Center.
HIV Structure, Lifecycle, and Replication
New Monogram Biosciences Testing Capabilities: Influenza, RSV, Ebola and Other Respiratory and Enveloped Viruses.
Viruses.
Combination of Drugs and Drug-Resistant Reverse Transcriptase Results in a Multiplicative Increase of Human Immunodeficiency Virus Type 1 Mutant Frequencies.
Einstein-Montefiore CFAR Virology Core Director: Dr. Ganjam V. Kalpana, Ph.D.
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
Simoa Accelerator Laboratory
Poor Reproducibility of HIV­1 Low-level Viraemia Results with 3 Commercial Real-time PCR Assays Jean Ruelle 1, Laurent Debaisieux 2, Ellen Vancutsem 3,
HIV, CD4, and More Karen Hutcherson Jenn Mann Elizabeth McCauley Michael Powers Courtney Wilson.
Viruses Chapter Nature of Viruses All viruses have same basic structure -Nucleic acid core surrounded by capsid Nucleic acid can be DNA or RNA;
AIDS supplement. History of HIV Originated in Africa in the late 1950’s Originally found in nonhuman primates and may have mutated First documented in.
HIV Cellular Pathogenesis III
DIAGNOSIS OF HIV INFECTION THE LABORATORY BY DR. K.BUJJIBABU.MD.
CCR5 Monoclonal Antibody PRO 140 Inhibited HIV-1 Resistant to Maraviroc, a Small Molecule CCR5 Antagonist Andre J Marozsan Progenics Pharmaceuticals, Inc.
HIV-1 Resistance - Implications For Clinicians Joseph J. Eron Jr., MD Professor of Medicine University of North Carolina.
1 Resistance and Tropism - Maraviroc Lisa K. Naeger, Ph.D. Division of Antiviral Products Food and Drug Administration April 24, 2007 FDA Antiviral Advisory.
West Nile Virus: Pathogenesis and Diagnostic Tools Maria Rios, PhD - Senior Staff Fellow Laboratory of Molecular Virology DETTD/OBRR/CBER/FDA WNV epidemic.
HIV-1 Drug Resistance Testing: A Practical Discussion Lee T. Bacheler, PhD VP Clinical Virology VircoLab, Inc Durham, NC.
Xenotropic Murine Leukemia Virus-Related Retrovirus: CCR Assay Development.
The Use of Pooled Viral Load Testing to Identify Antiretroviral Treatment Failure Davey Smith 1, Susanne May 2, Josué Perez-Santiago 1, Matthew Strain.
LOWERING THE DETECTION LIMITS OF HIV-1 VIRAL LOAD USING REAL-TIME IMMUNO-PCR FOR HIV-1 P24 ANTIGEN Niel T. Constantine, Ph.D., Daniel Edelman, M.S., Janet.
HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.
Clinical case 19 Lin, I-Yao (Sally). Case 19 Having been confined in the hospital for almost a month due recurrent pneumonia, Mr. XXX, 42 y/o, married,
Enfuvirtide for Drug-Resistant HIV Infection in North and South America Simon R. Bababeygy.
ImmunoPathogenesis of HIV Disease Overview of HIV Epidemic Basic biology of HIV-1 Stages of HIV Disease Viral and Cellular Dynamics after HAART HIV Therapy.
HIV-1 Resistance - Implications For Clinicians Joseph J. Eron Jr., MD Professor of Medicine University of North Carolina.
Retrovirus. Retroviridae –Retrovirus HTLV (human T-cell lymphotropic virus) –Lentivirus HIV.
HIV/AIDS.
Phar. Nhat Mang/ Roche Vietnam
Basics of Human Immunodeficiency Virus (HIV) Brian Rybarczyk, PhD University of North Carolina- Chapel Hill.
Immune reconstitution Anjie Zhen, PhD
HUMAN IMMUNODEFICIENCY VIRUS AND ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
1 ITN clinical trial analysis design – Transplantation example Cross-sectional and longitudinal clinical trials to assess tolerance Disease areas: Transplantation.
CATEGORY: VACCINES & THERAPEUTICS HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK HIV-1 Vaccines © The copyright for this work resides.
Cellular immune control of Human Immunodeficiency Virus (HIV) Dr. Ali Jalil Ali College of pharmacy.
HBV viral load 측정 및 임상적 의의 진단검사의학과이희주 Content v 임상적 의의 v 측정법.
Dawit Assefa Ethiopia Health and Nutrition Research Institute Dawit Assefa Ethiopia Health and Nutrition Research Institute Evaluation of an in-house HIV.
Create a concept map of the adaptive immune system.
Retrovirus.
Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;
Introduction Results Objectives Methods Conclusion Funding
AIDS supplement.
Content and Labeling of Tests Marketed as Clinical “Whole-Exome Sequencing” Perspectives from a cancer genetics clinician and clinical lab director Allen.
Protease.
Drug-resistant human immunodefiency virus
Diagnostics and Prognostics
Biotechnology.
Terminology HIV AIDS Acquired Human Immune Immunodeficiency Deficiency
Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner  Juan Lama, Aram Mangasarian,
Differential Detection of M184V/I Between Plasma Historical HIV Genotypes and Proviral DNA from PBMCs N Margot, R Ram, IR McNicholl, R Haubrich, C Callebaut.
Rapid Detection of HIV-1 subtype C Integrase resistance mutations by the Use of High-Resolution Melting Analysis Tendai Washaya BSc, Msc. Pre-PhD Student.
Presentation transcript:

Monogram Biosciences Pharma Collaborations A LabCorp Center of Excellence –

Monogram Biosciences Founded as ViroLogic, Nov 1995, South San Francisco, CA Acquired by LabCorp as wholly-owned subsidiary, Aug 2009 ~225 employees Virology/Oncology Commercial Assays Clinical management Drug/vaccine development Clinical Reference Laboratory CLIA/CAP accredited Science directed Over 175 peer-reviewed publications Ranked highly for intellectual property portfolio Has conducted over 200 projects involving every commercially-available HIV antiretroviral

Monogram Biosciences A LabCorp Center of Excellence LabCorp’s Platform 220,000 customers 31,000 employees 1,500 patient centers 440,000 samples per day 40 years Our mission is to be a leading provider of high science laboratory services that support clinical decision-making, enhance the management of laboratory information, and improve patient care.

Monogram’s Technologies are Offered Directly at Monogram and through Esoterix Clinical Trials Services, a Division of LabCorp Bioanalytical Labs Biomarker Discovery Companion Diagnostics Central Labs Esoteric Testing Small and large molecule Method development and validation LC/MS/MS Non-GLP discovery services Cell-based assays Dedicated labs for clinical trials Cranford, NJ Mechelen, Belgium Beijing, China Singapore Broad, validated test menu Test method harmonization 8 Centers of Excellence Coagulation Endocrinology Oncology Infectious disease Anatomic pathology Molecular pathology Flow cytometry Discovery and development GLP biomarker services MS-based assays Global expertise: Cranford, NJ Mechelen, Belgium San Diego, CA West Trenton, NJ Discovery, development, commercialization FDA experience IVD Trial Participation Successful PMA submission 40,000 ft2 biorepository Commitment to Quality Integrated Data Management Dedicated Project Management

Testing Services Across all Phases of Development Screening drug candidates Characterizing resistance Screening patients for enrollment Optimizing background therapy Characterizing treatment failure Defining clinical cut-offs Enhancing market positioning Discovery Preclinical Clinical Post-Marketing

HCV Testing Services

Monogram HCV Assays and Services Monogram is designed to be a ‘one stop shop’ to meet virology testing needs for clinical trials Monogram is applying its legacy of providing accurate, high throughput HIV testing to HCV Current HCV assays NS3: Sequencing & Phenotyping NS5b: Sequencing & Phenotyping NS5A: Sequencing & Phenotyping IL28B SNP Genotyping Subtyping/Genotyping and Viral Load Deep sequencing and clonal analysis

GenoSure® HCV – NS3/4a sequencing Monogram’s GenoSure HCV assay is now available for use in the clinic Designed to help determine patient susceptibility to the commercially available HCV drugs Validated to measure VL>2000 copies/ml

Monogram HIV Assays and Services for Clinical Research and Development Protease/Reverse Transcriptase Inhibitors PhenoSense® (phenotype) GenoSure® MG (genotype) PhenoSense® GT≤ (combination phenotype/genotype) Entry Inhibitor Susceptibility (T20) GenoSure PRIme® – genotyping PR/RT and Integrase in a single assay Trofile®, Trofile® DNA (Co-receptor Tropism) Integrase Susceptibility (phenotype; genotype) Assembly Inhibitor Susceptibility (phenotype; genotype) Replication Capacity & Sequencing Subtype Neutralizing Antibodies – for HIV and Influenza Clonal Analyses PhenoScreen® Novel Drug Testing Database queries Viral Load (Roche COBAS/Ampliprep TaqMan 2.0, Abbott Real Time)

HIV PR/RT Resistance Testing

PhenoSense HIV Cell Assay Resistance Test Vector DNA A-MLV env DNA + Transfection Infection 293-A Pseudovirions PR inhibitors added RT inhibitors added

Patient virus exhibits reduced susceptibility to the drug PhenoSense HIV Data Patient virus exhibits reduced susceptibility to the drug Patient: Control:

GenoSure MG Report Monogram’s GenoSure MG report combines LabCorp’s genotyping capabilities (for faster turnaround), and Monogram’s proprietary algorithm…

Measure of Drug Susceptibility Prediction of Drug Susceptibility Parallel Phenotype/Genotype Testing PhenoSense GT Assay (PSGT) Patient virus Phenotype Genotype RT-PCR PR-RT DNA Vector Assembly Resistance Test Vector Sequencing Transfection Recombinant Virus Resistance Mutations Infection Interpretation Measure of Drug Susceptibility Prediction of Drug Susceptibility Bioinformatics

Drug Resistance Testing: Genotype vs Phenotype Benefits and Limitations Genotyping Generates viral sequence (population) Identifies virus mixtures mix of susceptible and resistant virus species example: K103K/N Major Limitation: Interpretation of complex mutational patterns or reliance on algorithm Immature algorithms for new agents 15

Drug Resistance Testing: Genotype vs Phenotype Benefits and Limitations Genotyping Phenotyping Generates viral sequence (population) Identifies virus mixtures mix of susceptible and resistant virus species example: K103K/N Major Limitation: Interpretation of complex mutational patterns or reliance on algorithm Immature algorithms for new agents Direct measure of susceptibility Ease of interpretation Demonstrates effect of complex combinations of mutations Resistance and Cross-Resistance Re-sensitization Partial Activity Replication Capacity 16

Parallel Phenotype/Genotype Testing PSGT Report – Examples of Discordance 17

Parallel Phenotype/Genotype Testing PSGT Report – Examples of Discordance 18

Pol and Integrase Resistance Testing

GenoSure PRIme Monogram’s proprietary Pol assay allows sponsors and investigators to cost-effectively genotype PR/RT and Integrase in a single assay Please contact Monogram for technical details on this assay

Integrase Resistance Testing Monogram offers both genotyping and phenotyping to assist Integrase resistance in the clinical trial setting

HIV Tropism Testing

virus entry inhibitors added The Trofile Assay A. HIV env expression vector containing patient’s PCR-amplified HIV env fragments CD4 + CXCR4 + D. B. HIV genomic luciferase vector + Transfection Infection E. virus entry inhibitors added C. CD4 + CCR5 + F.

Trofile Report Trofile identifies the tropism of an individual patient's HIV strain – R5, X4, or a combination of these known as dual/mixed (D/M) Highly accurate, reproducible results using the complete HIV envelope (gp160) Clinically validated for selecting patients for CCR5 antagonist therapy

Trofile DNA Test Description: Cell-associated DNA isolated from PBMCs is incorporated into Monogram’s proprietary testing vector and run in a single-cycle recombinant assay to determine tropism. Product Specifications: Analytically validated to identify tropism in cell associated DNA. Sample Input: Whole blood; PBMC

Neutralizing Antibodies/Vaccine Development

Monogram Neutralization Assay gag pol P R A+  U3  env luciferase U87: CD4/CCR5/CXCR4 Neutralization Assay: Incubation with antibodies or patient plasma Y env luc a/b c/d gp120 gp41 (patient env gene) HEK-293 Vectors: Clone population of viral env present in plasma, cell culture, etc. Drug resistant PR/RT can be used for testing plasmas with RT inhibitors

Neutralization Assay Controls Three control viruses tested with every plasma: NL43 – neutralization sensitive lab strain JRCSF – well known primary isolate aMLV – specificity control: A test IC50 must >3X IC50 with aMLV to be called positive (green color) HIV+ Plasma Control: Tested with every virus in every run One control for every 7 sera tested N16, Z23 - Broad, low titered neutralizing capability Purpose of controls: Allow Monogram to assess run performance Allow PI to compare data across time

Antibody Neutralization Assay Inhibition Curve JRCSF aMLV Negative curve - No inhibition of aMLV by 2G12 Positive curve - IC50 = 0.56ug/ml aMLV = specificity control Anti-HIV antibodies will not inhibit aMLV

Assay Formats Multiple formats: HITS 4 dilutions For screening large numbers of sera Report % inhibition at each dilution CURVES 10 dilution curves with IC50, 80, 90, 95 Cutoff for positive is >3X IC50 with aMLV CURVES PLUS 10 dilution curve and IC50, etc. plus % inhibition at each dilution

Other Virology Testing and Services

Novel Drug Characterization Monogram can leverage its virus library and database to construct panels for drug characterization

Oncology Testing Services: VeraTag technology and HERmark assay

What is a “VeraTag” (VeraTag Reporter)? How VeraTag Works What is a “VeraTag” (VeraTag Reporter)? Three components Recognition element (most often antibodies) Cleavable tether (thio-ether or disulfide bond) Fluoroscein reporters (variable mass-charge) antigen antibody tether fluoroscein

HERmark Assay

HERmark Assay Workflow

HERmark Report Classification of HERmark positive, negative, or equivocal Lab Developed Test Validated to CLIA standards Performed in a central, CAP-certified clinical reference laboratory All cases reviewed by Board Certified Pathologists

Additional VeraTag Assays

For questions about Monogram technology or assay ordering: Andrew Gale Director, Pharma Collaborations agale@monogrambio.com